The price of Viatris Inc (NASDAQ:VTRS) shares last traded on Wall Street rose 1.24% to $10.64.
VTRS stock price is now -5.18% away from the 50-day moving average and -1.63% away from the 200-day moving average. The market capitalization of the company currently stands at $12.67B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $13 to $9, BofA Securities Downgraded its rating from Neutral to Underperform for Viatris Inc (NASDAQ: VTRS). On June 23, 2023, Barclays Downgraded its previous ‘Equal Weight’ rating to ‘Underweight’ on the stock keeping its target price maintained at $11, while ‘BMO Capital Markets’ rates the stock as ‘Market Perform’
In other news, Roman Brian, Chief Legal Officer sold 89,419 shares of the company’s stock on May 28 ’24. The stock was sold for $928,429 at an average price of $10.38. Upon completion of the transaction, the Chief Legal Officer now directly owns 67,723 shares in the company, valued at $0.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13 ’24, Mauro Anthony sold 250,000 shares of the business’s stock. A total of $3,023,700 was realized by selling the stock at an average price of $12.09. This leaves the insider owning 243,044 shares of the company worth $2.59 million. A total of 2.14% of the company’s stock is owned by insiders.
During the past 12 months, Viatris Inc has had a low of $8.74 and a high of $13.62. As of last week, the company has a debt-to-equity ratio of 0.91, a current ratio of 1.57, and a quick ratio of 1.08. The fifty day moving average price for VTRS is $11.2208 and a two-hundred day moving average price translates $10.81585 for the stock.
The latest earnings results from Viatris Inc (NASDAQ: VTRS) was released for 2024-03-31. The net profit margin was -0.37% and return on equity was -0.27% for VTRS. The company reported revenue of $3.66 billion for the quarter, compared to $3.73 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.76 percent.
Viatris Inc(VTRS) Company Profile
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
